CN110361494B - 异丙托溴铵气雾剂中杂质g的检测方法 - Google Patents
异丙托溴铵气雾剂中杂质g的检测方法 Download PDFInfo
- Publication number
- CN110361494B CN110361494B CN201910749526.2A CN201910749526A CN110361494B CN 110361494 B CN110361494 B CN 110361494B CN 201910749526 A CN201910749526 A CN 201910749526A CN 110361494 B CN110361494 B CN 110361494B
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- ipratropium bromide
- impurity
- volume ratio
- stage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012535 impurity Substances 0.000 title claims abstract description 71
- 229960001361 ipratropium bromide Drugs 0.000 title claims abstract description 64
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 title claims abstract description 64
- 239000000443 aerosol Substances 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000001514 detection method Methods 0.000 claims abstract description 42
- 238000010828 elution Methods 0.000 claims abstract description 17
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 19
- 239000012488 sample solution Substances 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 230000002378 acidificating effect Effects 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 150000002500 ions Chemical class 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000003085 diluting agent Substances 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000000337 buffer salt Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000012937 correction Methods 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- FBEVECUEMUUFKM-UHFFFAOYSA-M tetrapropylazanium;chloride Chemical compound [Cl-].CCC[N+](CCC)(CCC)CCC FBEVECUEMUUFKM-UHFFFAOYSA-M 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 239000012085 test solution Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 3
- ACQYZSFXPXXIHL-UHFFFAOYSA-N 2-phenylmethoxycarbonyl-3,4-dihydro-1h-isoquinoline-1-carboxylic acid Chemical compound C1CC2=CC=CC=C2C(C(=O)O)N1C(=O)OCC1=CC=CC=C1 ACQYZSFXPXXIHL-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 239000005456 alcohol based solvent Substances 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 claims description 2
- KSZDKSNRUYOJHR-UHFFFAOYSA-M dodecyl(trimethyl)azanium;hydrogen sulfate Chemical compound OS([O-])(=O)=O.CCCCCCCCCCCC[N+](C)(C)C KSZDKSNRUYOJHR-UHFFFAOYSA-M 0.000 claims description 2
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000005453 ketone based solvent Substances 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000011550 stock solution Substances 0.000 claims description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 claims description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 claims description 2
- SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 230000007547 defect Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract 1
- 238000011160 research Methods 0.000 description 14
- 238000000926 separation method Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 238000012795 verification Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001360 synchronised effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 241001137307 Cyprinodon variegatus Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
时间(min) | 流动相A% | 流动相B% |
0 | 80 | 20 |
32 | 80 | 20 |
63 | 40 | 60 |
68 | 80 | 20 |
75 | 80 | 20 |
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910560107 | 2019-06-26 | ||
CN2019105601074 | 2019-06-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110361494A CN110361494A (zh) | 2019-10-22 |
CN110361494B true CN110361494B (zh) | 2023-08-15 |
Family
ID=68223946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910749526.2A Active CN110361494B (zh) | 2019-06-26 | 2019-08-14 | 异丙托溴铵气雾剂中杂质g的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110361494B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1191535A (zh) * | 1995-08-01 | 1998-08-26 | 贝林格尔·英格海姆公司 | 新颖药物组合物及其用途 |
CN106038489A (zh) * | 2016-05-25 | 2016-10-26 | 华润双鹤药业股份有限公司 | 异丙托溴铵气雾剂 |
CN106349238A (zh) * | 2016-08-24 | 2017-01-25 | 山东省药学科学院 | 一种异丙托溴铵的制备方法 |
CN106831753A (zh) * | 2017-01-10 | 2017-06-13 | 武汉先路医药科技股份有限公司 | 一种异丙托溴铵的合成方法 |
-
2019
- 2019-08-14 CN CN201910749526.2A patent/CN110361494B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1191535A (zh) * | 1995-08-01 | 1998-08-26 | 贝林格尔·英格海姆公司 | 新颖药物组合物及其用途 |
CN106038489A (zh) * | 2016-05-25 | 2016-10-26 | 华润双鹤药业股份有限公司 | 异丙托溴铵气雾剂 |
CN106349238A (zh) * | 2016-08-24 | 2017-01-25 | 山东省药学科学院 | 一种异丙托溴铵的制备方法 |
CN106831753A (zh) * | 2017-01-10 | 2017-06-13 | 武汉先路医药科技股份有限公司 | 一种异丙托溴铵的合成方法 |
Non-Patent Citations (1)
Title |
---|
HPLC法测定异丙托溴铵原料药中的有关物质;陈红等;《中国药房》;20141231;第25卷(第12期);第1128~1131页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110361494A (zh) | 2019-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lou et al. | Simultaneous determination of paracetamol, pseudoephedrine, dextrophan and chlorpheniramine in human plasma by liquid chromatography–tandem mass spectrometry | |
WO2019242212A1 (zh) | 一种检测帕瑞昔布钠及合成中间体中有关物质的液相色谱方法 | |
Alvarez et al. | Identification and quantification of 4-methylethcathinone (4-MEC) and 3, 4-methylenedioxypyrovalerone (MDPV) in hair by LC–MS/MS after chronic administration | |
Xie et al. | Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study | |
Paek et al. | Hydrophilic interaction liquid chromatography–tandem mass spectrometry for the determination of levosulpiride in human plasma | |
Tseng et al. | Determination of sildenafil citrate adulterated in a dietary supplement capsule by LC/MS/MS | |
Shi et al. | A rapid and accurate UPLC/MS/MS method for the simultaneous determination of zolpidem and its main metabolites in biological fluids and its application in a forensic context | |
Ma et al. | Rapid analysis of tadalafil in human blood plasma and seminal plasma by liquid chromatography/tandem mass spectrometry | |
CN112198260B (zh) | 一种盐酸丙卡特罗药物制剂中工艺杂质含量的检测方法 | |
Vancea et al. | Determination of free captopril in human plasma by liquid chromatography with mass spectrometry detection | |
Shang et al. | Simultaneous determination of nitrendipine and hydrochlorothiazide in spontaneously hypertensive rat plasma using HPLC with on-line solid-phase extraction | |
CN110361494B (zh) | 异丙托溴铵气雾剂中杂质g的检测方法 | |
Smit et al. | Rapid and sensitive liquid chromatography–tandem mass spectrometry method for the quantitation of domperidone in human plasma | |
CN113804746A (zh) | 一种对尿液中的合成卡西酮类毒品进行快速定量的方法 | |
Bhagav et al. | Development and validation of stability indicating UV spectrophotometric method for the estimation of brimonidine tartrate in pure form, formulations and preformulation studies | |
Liu et al. | Quantitative Determination of Atorvastatin and Para-hydroxy Atorvastatin in Human Plasma by LC—MS—MS | |
Shah et al. | A rapid and specific approach for direct measurement of donepezil concentration in human plasma by LC‐MS/MS employing solid‐phase extraction | |
De Orsi et al. | Simultaneous determination of ephedrine and 2-imidazolines in pharmaceutical formulations by reversed-phase HPLC | |
US20120214875A1 (en) | Phenoxybenzamine assay | |
Li et al. | Simultaneous determination of omeprazole and domperidone in dog plasma by LC-MS method | |
Li et al. | Quantitative determination of spinosin in rat plasma by liquid chromatography-tandem mass spectrometry method | |
Lahoti et al. | Development and validation of RP-HPLC method for analysis of glipizide in guinea pig plasma and its application to pharmacokinetic study | |
Gao et al. | A sensitive LC–MS/MS method to quantify methylergonovine in human plasma and its application to a pharmacokinetic study | |
CN109270178B (zh) | 一种高效液相色谱法分离测定度他雄胺软胶囊中度他雄胺及有关物质的方法 | |
Li et al. | Simultaneous determination of ginkgolides A, B and K in human plasma by UPLC-MS/MS and its application to the pharmacokinetic study of Ginkgo Diterpene Lactone Meglumine Injection in humans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: No. 15 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610000 Applicant after: Sichuan Pu et Pharmaceutical Co.,Ltd. Address before: No. 15 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610000 Applicant before: SICHUAN PURUITE MEDICAL TECHNOLOGY Co.,Ltd. |
|
CB02 | Change of applicant information | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: No. 566 Antaiwu Road, Gaoxin District, Chengdu, Sichuan Province, 611730 Patentee after: Sichuan Pu et Pharmaceutical Co.,Ltd. Address before: No.15 Gaopeng Avenue, high tech Zone, Chengdu, Sichuan 610000 Patentee before: Sichuan Pu et Pharmaceutical Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |